Effect of Ulinastatin Assisted Somatostatin on Intestinal Mucosal Barrier Function and Inflammatory Indicators in Patients with Severe Acute Pancreatitis
Objective To analyze the effect of ulinastatin assisted somatostatin in patients with severe acute pancreatitis(SAP).Methods A total of 80 SAP patients admitted to Zaozhuang Hospital of Shandong Guoxin Health Nursing Group from April 2021 to April 2023 were selected as the research objects.According to the random number table method,they were divided into a control group and an observation group,with 40 cases in each group.Both groups were given routine medical treatment,among which the control group was treated with somatostatin,and the observation group was treated with ulinastatin on the basis of the control group,for 14 days in a row.The clinical efficacy,intestinal inflammatory reaction,intestinal mucosal barrier function and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 97.50%,which was higher than 77.50%of the control group,the difference was statistically significant(P＜0.05).After treatment,the levels of intestinal inflammatory response indexes and intestinal mucosal barrier function indexes in the observation group were lower than those in the control group,the differences between the two groups were statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion The effect of ulinastatin assisted somatostatin in the treatment of SAP is better,which is beneficial to reduce the level of inflammatory mediators in the body,enhance the intestinal mucosal barrier function,and has good application safetyx.
Severe acute pancreatitisUlinastatinSomatostatinIntestinal mucosal barrier functionIntestinal inflamma-tory reaction
NETL
NSTL
万方数据
